113 related articles for article (PubMed ID: 23214245)
21. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
Higano C; Shields A; Wood N; Brown J; Tangen C
Urology; 2004 Dec; 64(6):1182-6. PubMed ID: 15596194
[TBL] [Abstract][Full Text] [Related]
22. [Metabolic complications and quality of life in prostate cancer patients after receiving endocrine treatment].
Yuan JQ; Xu T; Zhang XW; Wang XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):88-94. PubMed ID: 23469798
[TBL] [Abstract][Full Text] [Related]
23. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
24. Androgen deficiency and bone mineral density in men with rheumatoid arthritis.
Stafford L; Bleasel J; Giles A; Handelsman D
J Rheumatol; 2000 Dec; 27(12):2786-90. PubMed ID: 11128664
[TBL] [Abstract][Full Text] [Related]
25. [Bone density and laboratory parameters of bone metabolism in patients with terminal heart disease].
Christ E; Linka A; Junga G; Odermatt M; Steinert H; Kiowski W; Schmid C
Schweiz Med Wochenschr; 1996 Sep; 126(37):1553-9. PubMed ID: 8927958
[TBL] [Abstract][Full Text] [Related]
26. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
27. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
28. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
[TBL] [Abstract][Full Text] [Related]
29. [Effects of exogenous testosterone on bone mineral density (BMD) and plasma levels of sex hormone and calcium, phosphorus in orchiectomized rabbits].
Wu Q; Li XY; Wang Y; Zhang H
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2004 Feb; 20(1):75-7. PubMed ID: 21162315
[TBL] [Abstract][Full Text] [Related]
30. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
[TBL] [Abstract][Full Text] [Related]
31. Bone mineral density in patients with pancreatic insufficiency and steatorrhea.
Morán CE; Sosa EG; Martinez SM; Geldern P; Messina D; Russo A; Boerr L; Bai JC
Am J Gastroenterol; 1997 May; 92(5):867-71. PubMed ID: 9149203
[TBL] [Abstract][Full Text] [Related]
32. Femoral neck osteopenia in patients with inflammatory bowel disease.
Pollak RD; Karmeli F; Eliakim R; Ackerman Z; Tabb K; Rachmilewitz D
Am J Gastroenterol; 1998 Sep; 93(9):1483-90. PubMed ID: 9732930
[TBL] [Abstract][Full Text] [Related]
33. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
34. Association of severe haemophilia A with osteoporosis: a densitometric and biochemical study.
Gallacher SJ; Deighan C; Wallace AM; Cowan RA; Fraser WD; Fenner JA; Lowe GD; Boyle IT
Q J Med; 1994 Mar; 87(3):181-6. PubMed ID: 8208906
[TBL] [Abstract][Full Text] [Related]
35. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
[TBL] [Abstract][Full Text] [Related]
36. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
[TBL] [Abstract][Full Text] [Related]
37. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
38. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
[TBL] [Abstract][Full Text] [Related]
39. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
40. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
